Noritoshi Kobayashi

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

ASO Visual Abstract: Clinical Course and Risk Factors for Malignant Progression in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata.

ASO Visual Abstract: Clinical Course and Risk Factors for Malignant Progression in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata.

Journal: Annals of surgical oncology

Published: June 04, 2026

Reply to the letter regarding "Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study".

Reply to the letter regarding "Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study".

Journal: Annals of nuclear medicine

Published: April 03, 2026

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors.

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors.

Journal: Cancers

Published: March 22, 2026

Effectiveness and Safety of Immunosuppressive Therapy in Recurrent Autoimmune Pancreatitis.

Effectiveness and Safety of Immunosuppressive Therapy in Recurrent Autoimmune Pancreatitis.

Journal: Internal medicine (Tokyo, Japan)

Published: March 04, 2026

Clinical Course and Risk Factors for Malignant Progression in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata.

Clinical Course and Risk Factors for Malignant Progression in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata.

Journal: Annals of surgical oncology

Published: February 02, 2026

Analysis of Risk Factors for Post-ERCP Pancreatitis in Patients with Cholangiocarcinoma.

Analysis of Risk Factors for Post-ERCP Pancreatitis in Patients with Cholangiocarcinoma.

Journal: Diagnostics (Basel, Switzerland)

Published: January 24, 2026

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

Journal: Annals of nuclear medicine

Published: December 20, 2025

Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).

Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).

Journal: Journal of gastroenterology

Published: September 02, 2025

Evaluation of Additional Treatment for Residual Cases After Endoscopic Papillectomy of Duodenal Ampullary Tumors.

Evaluation of Additional Treatment for Residual Cases After Endoscopic Papillectomy of Duodenal Ampullary Tumors.

Journal: DEN open

Published: September 01, 2025

Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in 177Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial.

Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in 177Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial.

Journal: JMIR research protocols

Published: August 29, 2025

Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster

Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 21, 2025

Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001).

Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001).

Journal: Neuroendocrinology

Published: July 24, 2025

Showing 1-12 of 149

Last Updated: 09/26/2026